This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are
refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).
This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232
in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed
TKI treatments.